Treatment of lupus nephritis: Facing the era of immunotherapy

Panminerva Medica

Volumn 50, Issue 3, 2008, Pages 235-245

  Aran, A A ^a   Putterman, C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

B lymphocytes; Immunotherapy; Lupus erythematosus, systemic; Lupus nephritis

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTOANTIBODY; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; BIOSYNTHESIS; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS NEPHRITIS; MESENCHYMAL STEM CELL TRANSPLANTATION; METHODOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-LYMPHOCYTES; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MESENCHYMAL STEM CELL TRANSPLANTATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 57349150240     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413-24.
2. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment for lupus nephritis. Cochrane Database Syst Rev. 2004;(1):CD002922.
3. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
4. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40.
5. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003;62:435-9.
6. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus 2008;17:426-30.
7. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007;2:968-75.
8. Aspreva's Cell Cept fails late-stage superiority study [Internet]. Available from http://www.fiercebiotech.com/story/aspreva-s-cellcept-fails-late- stage-superiority-study/2007-06-27 [cited September 19, 2008].
9. Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized controlled Aspreva Lupus Management Study (ALMS). Lupus 2007; 16:972-80.
10. Isenberg D, Appel G, Dooley MA et al. Mycophenolate Mofetil compared with intravenous cyclophosphamide as induction for lupus nephritis: ALMS results and BILAG responses. EULAR 2008, Abstract Session: Lupus from clinic to new treatments [OP-0018).
11. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
12. Bertsias G, loannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.
13. Prakash A, Jarvis B. Leflunomide-a review of its use in active rheumatoid arthritis. Drugs 1999, 58:1137-64.
14. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor kappa B activation and gene expression. J Immunol 1999;162:2095-102.
15. Kale VP, Bichile LS. Leflunomide: a novel disease modifying antirheumatic drug. J Postgrad Med 2004;50:154-7.
16. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008;17:638-44.
17. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 2006; 18:468-75.
18. Ramanujam M, Davidson A. Targeting of the immune system in systemic lupus erythematosus. Expert Rev Mol Med 2008; 10:2.
19. Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int 2008;73:261-8.
20. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus. J Exp Med 1999;189:1639-48.
21. Matsumoto K, Watanabe N, Akikusa B, Kurasawa K, Matsumura R, Saito Y et al. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum 2003;48:486-94.
22. Abetimus. Abetimus sodium, LJP 394. BioDrugs 2003;17:212-5.
23. Mosca M, Baldini C, Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2007;8:873-9.
24. Cardiel MH. Abetimus sodium: a new therapy for delaying the time to and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert Opin Investig Drugs 2005; 14:77-88.
25. Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24:314-8.
26. Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-65.
27. Strand V, Aranow C, Cardiel MH, Alarcón-Segovia D, Furie R, Sherrer Y et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86.
28. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80.
29. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7.
30. Salama AD, Pusey C. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006;2:221-30.
31. Molloy ES, Cabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008 [Epub ahead of print].
32. Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P et al. Rituximab therapy for childhood onset systemic lupus erythematosus. J Pediatr 2006;148:623-7.
33. Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang ML et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996;5:551-62.
34. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dörner T. Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann Rheum Dis 2008;67:450-7.
35. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:108.
36. Wallace D, Hobbs K, Houssiau F et al. Randomized controlled trials of epratuzumab (anti CD-22 mab targeting B cells) revel clinically meaningful reductions in corticosteroid (cs) use with favorable safety profile in moderate and severe flaring SLE patients. EULAR 2008, Abstract Session: SLE, Sjogren's and APS Clinical aspects and treatment, [THU0238].
37. Clinical Trials.gov [Internet]. Available from www.clinicaltrials.gov. [cited September 19, 2008].
38. Cohen RA, Bayliss G, Crispin JC, Kane-Wanger GF, Van Beek CA, Kyttaris VC et al. T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clin Immunol 2008;128:1-7.
39. Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus Lupus 2004;13:377-80.
40. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an open label trial. Arthritis Rheum 2005;52:501-13.
41. Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K et al. Effects of anti-CD 154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003;48:495-506.
42. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27.
43. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001, 28:95-101.
44. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8.
45. Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Ann N Y Acad Sci 1997;815:392-400.
46. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994;265:1225-7.
47. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-6.
48. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis. 2006 Nov; 65 Suppl 3:iii34-6.
49. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
50. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9.
51. [No authors listed]. Belimumab: anti-BLyS human monoclonal antibody, BmAb: human monoclonal antibody to B-lymphocyte stimulator. Drugs RD 2008;9:197-202.
52. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham WW et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocytestimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109.
53. Furie R, Petri M, Weisman MH et al. Belimumab (fully humanized monoclonal antibody to Blys) improved or stabilized systemic lupus erythematosus (SLE) disease activity and reduced flare rate during 3 years of therapy. EULAR 2008. Abstract Session: Lupus from clinic to new treatments. [OP-0017]
54. Ginzler EM, Wallace DJ, Chatham W et al. Belimumab (fully human monoclonal antibody to Blys) reduced steroid use in systemic lupus erythematosus (SLE) patients during 3 years of therapy. EULAR 2008. Session Info: SLE, Sjögren's and APS Clinical aspects and treatment. [THU0253].
55. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-91.
56. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW) F1 mice. Am J Pathol 1994;144:927-37.
57. Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998;112:397-402.
58. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Antiinterleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006;119:296-305.
59. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factoralpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995;26:558-64.
60. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
61. Buhaescu I, Covic A, Deray G. Treatment of proliferative lupus nephritis-a critical approach. Semin Arthritis Rheum 2007;36:224-37.
62. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9.
63. Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007;56:274-9.
64. Aringer M, Houssiau F, Graninger WB et al. TNF blockade in SLE: long term efficacy and safety aspects of open-label infliximab. EULAR 2008. Abstract Session: SLE, Sjogren's and APS Clinical aspects and treatment, [THU0235].
65. Van Laar JM, Tyndall A. Cellular therapy of systemic sclerosis. Curr Rheumatol Rep 2008;10:189-94.
66. Marmont AM, Gualandi F, van Lint MT, Guastoni C, Bacigalupo A. Long term complete remission of severe nephrotic syndrome secondary to diffuse global (IV-G) lupus nephritis following autologous, haematopoietic peripheral stem (CD34+) cell transplantation. Lupus 2006;15:44-6.
67. El-Badri NS, Maheshwari A, Sanberg PR. Mesenchymal stem cells in autoimmune disease. Stem Cells Dev 2004;13:463-72.